• Filter by category

The Allay® Aortic Stent wins the 2024 Prix Galien for Most Promising Design

The Prix Galien, often likened to the Nobel Prize of medical innovation on the international stage, celebrates the most significant advancements in healthcare.

The Allay® Aortic Stent wins the 2024 Prix Galien for Most Promising Design

The Prix Galien, often likened to the Nobel Prize of medical innovation on the international stage, celebrates the most significant advancements in healthcare.

Originally awarded in France, this prestigious award has expanded to 15 different countries, reflecting the growing involvement of companies in biomedical research and development. Since 2023, The award has been divided into two events: The Prix Galien Medical Devices and The Prix Galien pharmaceuticals.

This year, The Galien Ceremony for Medical Devices took place in Brussels, coinciding with the MedTech Meetup where Diane, Chief Strategy Officer of Intressa Vascular, pitched our project.

For Intressa Vascular, this recognition as medical device with the most promising design from the Galien Foundation acknowledges the innovative characteristics of the stent, which relays on its mechanical properties and 3D-porosity to provide extensive coverage of the dissected aorta, aiming at reducing the need for reintervention and the frequency of side effects.

The satisfaction is even greater as this award comes from experts in medical and academic fields, underscoring our ability to meet the critical needs of the medical community.

This victory strengthens our determination to continue our mission of innovation and supports our efforts in bringing a better treatment option for aortic dissection.

About Intressa Vascular

Intressa Vascular (www.intressavascular.com), located in Gembloux, Belgium, is providing innovative solutions to address life-threatening cardiovascular conditions such as aortic dissection. Intressa Vascular has developed a proprietary braiding technology platform allowing to produce multilayer stent. Its Allay® Aortic Stent is the only treatment for Type B aortic dissections (TBAD) and residual dissections designed to recentralize blood flow inside the true lumen while preserving branch perfusion, via a streamlined procedure with a low risk of complications.

For further information, please contact:

Pierre Douette, CEO

Intressa Vascular

P. +32 (0)81 71 99 41

E. info@intressavascular.com

W. www.intressavascular.com

Denis Gestin is appointed to Intressa Vascular Board of Directors

Former medical device industry top executive, Denis Gestin, joins Intressa Vascular Board of Directors as an independent board member.

Former medical device industry top executive, Denis Gestin, joins Intressa Vascular Board of Directors as an independent board member

Gembloux, Belgium, January 9, 2024 – Intressa Vascular SA, a clinical-stage MedTech company using its proprietary multilayer stent braiding technology to develop an innovative stent for aortic dissection, today announces the appointment of Denis Gestin as independent director.

Former medical device top executive, Denis Gestin, brings more than thirty years of experience in the management and commercial development of medical technologies companies, having held positions as SVP for Abbott and President of the International Division (OUS) at St. Jude Medical. Today active in the Board of Directors of several start-ups, Denis shares Intressa Vascular’s value and dedication to bringing new options to patients with aortic dissection, a life-threatening cardiovascular condition with poor outcome and suboptimal treatment options on an addressable market of more than EUR 2 billion.

Denis Gestin will be a critical member of the Board of Director at Intressa Vascular, to advance the company’s product development, including clinical studies and regulatory pathways, and prepare market adoption of the multilayer stent in aortic dissection”, says Philippe Felten, Chairman of the Board.

I believe that Intressa Vascular is well positioned to make a great impact on the treatment of aortic dissection through their unique multilayer stent braiding technology, said Denis Gestin. I am excited to join Intressa Vascular and work with the distinguished and accomplished team of employees, directors and scientific advisors to better support patients facing such life-threatening disease as aortic dissection”, says Denis Gestin, Director of the Board.

We are very excited to welcome Denis as an independent board member. As we are progressing closer to the market, his expertise and international exposure both as MedTech executive and Director will be highly valuable and will complement our team with high impact”, says Pierre Douette, CEO.

About Intressa Vascular

Intressa Vascular (www.intressavascular.com), located in Gembloux, Belgium, is providing innovative solutions to address life-threatening cardiovascular conditions such as aortic dissection. Intressa Vascular has developed a proprietary braiding technology platform allowing to produce multilayer stent. Its Allay® Aortic Stent is the only treatment for Type B aortic dissections (TBAD) and residual dissections designed to recentralize blood flow inside the true lumen while preserving branch perfusion, via a streamlined procedure with a low risk of complications.

For further information, please contact:

Pierre Douette, CEO

Intressa Vascular

P. +32 (0)81 71 99 41

E. info@intressavascular.com

W. www.intressavascular.com

Intressa Vascular secures EUR 13 million in financing

Intressa Vascular secures EUR 13 million in financing to support the development of its innovative multilayer Allay™ Aortic Stent for the treatment of aortic dissection

Intressa Vascular secures EUR 13 million in financing to support the development of its innovative multilayer Allay® Aortic Stent for the treatment of aortic dissection

Press Release – 17/10/2023

Intressa Vascular is using its proprietary multilayer stent braiding technology to develop an innovative stent for aortic dissection, a life-threatening cardiovascular condition affecting worldwide 300,000 patients annually. The company has secured EUR 13 million in financing with the continued support of both existing and new investors and received an additional support from the Walloon Region. Funds are aimed at clinical studies and product registration purposes.

Gembloux, Belgium, October 17, 2023 – Intressa Vascular SA, a clinical-stage MedTech company, today announces the successful raising of 13 million euros in financing to support the development of its innovative multilayer stent device, the Allay® Aortic Stent, in the treatment of aortic dissection. The EUR 10 million equity round has been completed by existing investors Noshaq, Yonjin Capital, the White Fund, WE Life Sciences, CPH Bank, and a series of historical investors, who are joined by AMERIGO, the Walloon investment fund supporting new business opportunities to foster growth. A complementary EUR 3 million in non-dilutive funding is provided by the Walloon Region (DGO6) to support the evaluation of adjacent indications of the multilayer stent technology platform in aortic dissection.

Aortic dissection is a life-threatening cardiovascular condition with poor clinical outcome. Current treatment options are suboptimal, requiring complex procedures and associated with a high rate of complications, including paraplegia and high mortality.

Intressa Vascular uses its proprietary technology platform to develop and manufacture multilayer stents for various cardiovascular applications. The company’s lead product, the Allay® Aortic Stent, has been evaluated for the endovascular treatment of aortic dissection, with first long-term results presented at Charing Cross International Symposium, London, in April 2023 and a landmark publication being prepared.

“Since our last round of financing, we have gathered substantial data highlighting the potential of the Allay® Aortic Stent in the treatment of aortic dissection. This compelling evidence has generated commitment and support from investors. Despite the challenging financing context, we are happy to secure this new financing that provides the team the necessary means to continue delivering on our plan in aortic dissection”, adds Philippe Felten, chairman of the board.

“Patients with aortic dissection deserve more treatment options, tailored to their specific needs; bringing such options to the patients and physicians is the daily commitment of everyone at Intressa Vascular. With this new financing, we will be able to advance the company’s clinical development and product registration activities, primarily in Europe, and further anchor and develop the organization locally to deliver on an addressable market segment worth more than EUR 2 billion. We thank our investors and Amerigo for their support”, says Pierre Douette, Intressa Vascular’s CEO.

About Intressa Vascular

Intressa Vascular (www.intressavascular.com), located in Gembloux, Belgium, is providing innovative solutions to address life-threatening cardiovascular conditions such as aortic dissection. Intressa Vascular has developed a proprietary braiding technology platform allowing to produce multilayer stent. Its Allay® Aortic Stent is the only treatment for Type B aortic dissections (TBAD) and residual dissections designed to reopen the true lumen along the dissected aorta while preserving branch perfusion, via a streamlined procedure with a low risk of complications.

About Noshaq

Noshaq is an investment fund with a portfolio of more than 450 companies, many of them being high-potential SMEs in technological sectors. Over the years, Noshaq has developed a variety of financing vehicles, especially in the life science field. Noshaq is committed to developing sectorial expertise and structuring ecosystems that give companies the favorable conditions they need to better respond to the new challenges of today and tomorrow.

www.noshaq.be

About Yonjin Capital

Yonjin is a specialized investment company under Yonjin Group, focusing on Private Equity investment and Fund management. The VC team at Yonjin is a market leader in Chinese venture capital, with technical expertise in TMT (technology, media, telecom), medical and healthcare as well as the new material development sectors. In addition, the vast experience with internal operation and investment management allows for remarkable investment performance and client trust.

http://www.yjventure.com 

About White Fund

White Fund is an early-stage private equity fund entirely dedicated to the medical device sector. The targets are promising ‘early-stage’ companies, with at least a proof of concept of their technology and objective market traction indicators. White Fund aims to support the pre-commercialization stages of projects and the start of sales, with an exit target of five to seven years. The geographical scope of the investment is Belgium, without excluding the possibility of opportunities in neighboring areas.

www.whitefund.be

About WE Life Sciences

WE Life Sciences invests in Wallonia’s “Local Heroes” – researchers and entrepreneurs leveraging innovation to foster a sustainable and equitable global economy. Emphasizing diversity and cross-fertilization, they support a wide range of health sector companies at various developmental stages and driven by a long-term vision. As a pioneer, premature, and patient investor, WE Life Sciences encourages entrepreneurs to explore new areas, strengthening Wallonia’s economic health.

www.wallonie-entreprendre.be

About CPH Bank

Established in 1930, CPH Bank (www.cph.be) is a Belgian regional cooperative bank. With around 30 agencies and 220 employees, CPH Bank provides a range of payment, savings and loans products and services to individuals and SMEs in Hainaut, Namurois and Walloon Brabant. Last private bank in the French-speaking part of Belgium, Banque CPH has a sound financial position. In the last years, the bank has developed a limited activity of private equity in innovative companies.

www.cph.be

About Amerigo

Initiated in the wake of the economic support measures taken since the start of the pandemic and contributing to the objectives of the Wallonia Recovery Plan, AMERIGO deploys funds to support the recovery and growth of Walloon businesses.

About DGO6

The Operational Directorate-General for Economy, Employment and Research (DGO6), belonging to the Walloon Public Service (https://recherche.wallonie.be/), is the legal administration in charge of funding applied research for new technologies and energy for industries, academia and research centers, as well as of related international scientific co-operation. It is the key advisory body for the Regional government authorities involving research and innovation policy.

For further information, please contact

Pierre Douette, CEO

Intressa Vascular

Long-term results of the prospective aortic dissection DRAGON study presented at CX2023

On April 27, 2023, the investigators, represented by Prof. Dr Victor Costache, presented at CX Symposium 2023 the “Long-term safety outcomes of patients with type B aortic dissection treated with multilayer stents: Results from a prospective multicenter pilot study”

Long-term results of the prospective aortic dissection DRAGON study presented at CX2023

Avril 2023

On April 27, 2023, the investigators, represented by Prof. Dr Victor Costache, presented at CX Symposium 2023 the “Long-term safety outcomes of patients with type B aortic dissection treated with multilayer stents: Results from a prospective multicenter pilot study” (https://www.cxsymposium.com).

In this study, initiated in 2016 and conducted in Europe, 24 patients with high-risk type B aortic dissection (TBAD) were treated with multilayer stents. The results, after a mean follow-up of 55 months (38-76 months) are promising with high survival rate (5-year survival estimated at 87.5%), no paraplegia, no stroke, no end-organ ischemia, no aortic-related reintervention, and no device deficiencies.

Put in perspective of the previously published cases and prospective registry reporting the use of the multilayer stent in aortic dissection, these results indicate that the multilayer stent could be a safe long-term treatment option for high-risk TBAD patients, showing high overall survival without reinterventions, and with preserved long-term end-organ perfusion.

To watch the on-demand version: https://www.cxsymposium.com

1 2